Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simianhuman immunodeficiency virus infection

Journal of Virology

Volumn 89, Issue 16, 2015, Pages 8334-8345

  Saunders, Kevin O ^a   Wang, Lingshu ^a   Joyce, M Gordon ^a   Yang, Zhi Yong ^a,e   Balazs, Alejandro B ^b   Cheng, Cheng ^a   Ko, Sung Youl ^a   Kong, Wing Pui ^a   Rudicell, Rebecca S ^a,e   Georgiev, Ivelin S ^a   Duan, Lijie ^c   Foulds, Kathryn E ^a   Donaldson, Mitzi ^a   Xu, Ling ^a,e   Schmidt, Stephen D ^a   Todd, John Paul ^a   Baltimore, David ^d   Roederer, Mario ^a   Haase, Ashley T ^c   Kwong, Peter D ^a   Rao, Srinivas S ^a   Mascola, John R ^a   Nabel, Gary J ^a,e   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d California Institute of Technology   (United States)

^e SANOFI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ANTIBODY; CYCLOSPORIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ANTIBODY GENE; CONTROLLED STUDY; GENE TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; AMINO ACID SEQUENCE; ANIMAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENE VECTOR; GENETICS; HIV INFECTIONS; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; MOLECULAR MODEL; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; RHESUS MONKEY; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; PRIMATES; SIMIAE; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; CYCLOSPORINE; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MACACA MULATTA; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84937421013     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00908-15     Document Type: Article

References (58)

1. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M. 2009. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83:188-199. http://dx.doi.org/10.1128/JVI.01583-08.
2. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13: 1032-1034. http://dx.doi.org/10.1038/nm1624.
3. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. 2014. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28:163-169. http://dx.doi.org/10.1097/QAD.0000000000000106.
4. Ruprecht RM. 2009. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches. Methods Mol Biol 525:559-566. http://dx.doi.org/10.1007/978-1-59745-554-1_31.
5. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. Annu Rev Immunol 28:413-444. http://dx.doi.org/10.1146/annurev-immunol-030409-101256.
6. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103. http://dx.doi.org/10.1126/science.1213256.
7. Bonsignori M, Montefiori DC, Wu X, Chen X, Hwang KK, Tsao CY, Kozink DM, Parks RJ, Tomaras GD, Crump JA, Kapiga SH, Sam NE, Kwong PD, Kepler TB, Liao HX, Mascola JR, Haynes BF. 2012. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol 86:4688-4692. http://dx.doi.org/10.1128/JVI.07163-11.
8. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406-412. http://dx.doi.org/10.1038/nature11544.
9. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
10. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637. http://dx.doi.org/10.1126/science.1207227.
11. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. http://dx.doi.org/10.1038/nature10373.
12. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
13. Kwong PD, Mascola JR, Nabel GJ. 2013. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13:693-701. http://dx.doi.org/10.1038/nri3516.
14. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, Schmidt SD, Chuang GY, Druz A, Soto C, Yang Y, Zhang B, Zhou T, Todd JP, Lloyd KE, Eudailey J, Roberts KE, Donald BR, Bailer RT, Ledgerwood J, Program NCS, Mullikin JC, Shapiro L, Koup RA, Graham BS, Nason MC, Connors M, Haynes BF, Rao SS, Roederer M, Kwong PD, Mascola JR, Nabel GJ. 2014. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 88:12669-12682. http://dx.doi.org/10.1128/JVI.02213-14.
15. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen X, Todd JP, Letvin NL, Huang J, Nason MC, Hoxie JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ. 2014. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 6:243ra288. http://dx.doi.org/10.1126/scitranslmed.3008992.
16. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, Burton DR. 2012. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 109:18921-18925. http://dx.doi.org/10.1073/pnas.1214785109.
17. Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR. 2002. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 76:8769-8775. http://dx.doi.org/10.1128/JVI.76.17.8769-8775.2002.
18. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, Van Roey M, Jooss K. 2005. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23:584-590. http://dx.doi.org/10.1038/nbt1087.
19. Fang J, Yi S, Simmons A, Tu GH, Nguyen M, Harding TC, Van Roey M, Jooss K. 2007. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther 15:1153-1159.
20. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481:81-84. http://dx.doi.org/10.1038/nature10660.
21. Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, An DS, Baltimore D. 2014. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 20:296-300. http://dx.doi.org/10.1038/nm.3471.
22. Evans DT, Silvestri G. 2013. Nonhuman primate models in AIDS research. Curr Opin HIV AIDS 8:255-261. http://dx.doi.org/10.1097/COH.0b013e328361cee8.
23. Kramer VG, Siddappa NB, Ruprecht RM. 2007. Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr HIV Res 5:642-655. http://dx.doi.org/10.2174/157016207782418506.
24. Mascola JR. 2003. Defining the protective antibody response for HIV-1. Curr Mol Med 3:209-216. http://dx.doi.org/10.2174/1566524033479799.
25. Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O'Dell S, Feng Y, Mascola JR, Wyatt RT, Karlsson Hedestam GB. 2012. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med 4:142ra96. http://dx.doi.org/10.1126/scitranslmed.3003752.
26. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR. 2009. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15:901-906. http://dx.doi.org/10.1038/nm.1967.
27. Balazs AB, West AP, Jr. 2013. Antibody gene transfer for HIV immunoprophylaxis. Nat Immunol 14:1-5. http://dx.doi.org/10.1038/nri3591.
28. West AP, Jr, Galimidi RP, Gnanapragasam PN, Bjorkman PJ. 2012. Single-chain Fv-based anti-HIV proteins: potential and limitations. J Virol 86:195-202. http://dx.doi.org/10.1128/JVI.05848-11.
29. Ehrlich PH, Harfeldt KE, Justice JC, Moustafa ZA, Ostberg L. 1987. Rhesus monkey responses to multiple injections of human monoclonal antibodies. Hybridoma 6:151-160. http://dx.doi.org/10.1089/hyb.1987.6.151.
30. van Meer PJ, Kooijman M, Brinks V, Gispen-de Wied CC, Silva-Lima B, Moors EH, Schellekens H. 2013. Immunogenicity of mAbs in nonhuman primates during nonclinical safety assessment. MAbs 5:810-816. http://dx.doi.org/10.4161/mabs.25234.
31. Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang ZY, Ko SY, Chen X, Schmidt SD, Haase AT, Todd JP, Bao S, Kwong PD, Rao SS, Mascola JR, Nabel GJ. 2015. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J Virol 89: 5895-5903. http://dx.doi.org/10.1128/JVI.00210-15.
32. Vandenberghe LH, Wang L, Somanathan S, Zhi Y, Figueredo J, Calcedo R, Sanmiguel J, Desai RA, Chen CS, Johnston J, Grant RL, Gao G, Wilson JM. 2006. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 12:967-971. http://dx.doi.org/10.1038/nm1445.
33. Mingozzi F, Chen Y, Murphy SL, Edmonson SC, Tai A, Price SD, Metzger ME, Zhou S, Wright JF, Donahue RE, Dunbar CE, High KA. 2012. Pharmacological modulation of humoral immunity in a nonhuman primate model ofAAVgene transfer for hemophilia B. Mol Ther 20:1410-1416. http://dx.doi.org/10.1038/mt.2012.84.
34. Wu X, Zhang Z, Schramm CA, Joyce MG, Do Kwon Y, Zhou T, Sheng Z, Zhang B, O'Dell S, McKee K, Georgiev IS, Chuang GY, Longo NS, Lynch RM, Saunders KO, Soto C, Srivatsan S, Yang Y, Bailer RT, Louder MK, NISC Comparative Sequencing Program, Mullikin JC, Connors M, Kwong PD, Mascola JR, Shapiro L. 2015. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 161:470-485. http://dx.doi.org/10.1016/j.cell.2015.03.004.
35. Georgiev IS, Rudicell RS, Saunders KO, Shi W, Kirys T, McKee K, O'Dell S, Chuang GY, Yang ZY, Ofek G, Connors M, Mascola JR, Nabel GJ, Kwong PD. 2014. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol 192:1100-1106. http://dx.doi.org/10.4049/jimmunol.1302515.
36. Lo BK. 2004. Antibody humanization by CDR grafting. Methods Mol Biol 248:135-159.
37. Donaldson MM, Kao SF, Eslamizar L, Gee C, Koopman G, Lifton M, Schmitz JE, Sylwester AW, Wilson A, Hawkins N, Self SG, Roederer M, Foulds KE. 2012. Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies. J Immunol Methods 386:10-21. http://dx.doi.org/10.1016/j.jim.2012.08.011.
38. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, Wang K, Bao S, Kraemer TD, Rath T, Zeng M, Schmidt SD, Todd JP, Penzak SR, Saunders KO, Nason MC, Haase AT, Rao SS, Blumberg RS, Mascola JR, Nabel GJ. 2014. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514:642-645. http://dx.doi.org/10.1038/nature13612.
39. Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, Tryniszewska E, Lewis MG, Van Cott TC, Hirsch V, Woodward R, Gibson A, Grace M, Dobratz E, Markham PD, Hel Z, Nacsa J, Klein M, Tartaglia J, Franchini G. 2002. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 76:292-302. http://dx.doi.org/10.1128/JVI.76.1.292-302.2002.
40. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immuno-deficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-1905. http://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002.
41. Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, Mascola JR. 2009. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol 83:10892-10907. http://dx.doi.org/10.1128/JVI.01142-09.
42. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES, Jr, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M, Jr, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M. 2015. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519:87-91. http://dx.doi.org/10.1038/nature14264.
43. Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D. 2013. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol 31:647-652. http://dx.doi.org/10.1038/nbt.2618.
44. McCarty DM, Monahan PE, Samulski RJ. 2001. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8:1248-1254. http://dx.doi.org/10.1038/sj.gt.3301514.
45. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347. http://dx.doi.org/10.1128/JVI.75.17.8340-8347.2001.
46. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membraneproximal external region protect against mucosal challenge by simianhuman immunodeficiency virus SHIVBa-L. J Virol 84:1302-1313. http://dx.doi.org/10.1128/JVI.01272-09.
47. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15:951-954. http://dx.doi.org/10.1038/nm.1974.
48. Mascola JR, Stiegler G, Van Cott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207-210. http://dx.doi.org/10.1038/72318.
49. Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, Diskin R, Bjorkman PJ, Eckhaus MA, Klein F, Mouquet H, Cetrulo Lorenzi JC, Gazumyan A, Burton DR, Nussenzweig MC, Martin MA, Nishimura Y. 2014. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 211:2061-2074. http://dx.doi.org/10.1084/jem.20132494.
50. Takeuchi H, Ishii H, Kuwano T, Inagaki N, Akari H, Matano T. 2012. Host cell species-specific effect of cyclosporine A on simian immunodeficiency virus replication. Retrovirology 9:3. http://dx.doi.org/10.1186/1742-4690-9-3.
51. Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, Sodroski J, Gottlinger HG. 1994. Functional association of cyclophilin A with HIV-1 virions. Nature 372:363-365. http://dx.doi.org/10.1038/372363a0.
52. Braaten D, Franke EK, Luban J. 1996. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J Virol 70:4220-4227.
53. Hwang WY, Foote J. 2005. Immunogenicity of engineered antibodies. Methods 36:3-10. http://dx.doi.org/10.1016/j.ymeth.2005.01.001.
54. Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, Mc-Clintock D, Bellinger DA, Couto LB, Nichols TC, High KA. 2002. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 13:1281-1291. http://dx.doi.org/10.1089/104303402760128513.
55. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzman GJ, High KA. 1999. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5:56-63. http://dx.doi.org/10.1038/4743.
56. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B. 2003. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963-2972. http://dx.doi.org/10.1182/blood-2002-10-3296.
57. Bretscher P, Cohn M. 1970. A theory of self-nonself discrimination. Science 169:1042-1049. http://dx.doi.org/10.1126/science.169.3950.1042.
58. Zinkernagel RM. 2000. Localization dose and time of antigens determine immune reactivity. Semin Immunol 12:163-171, discussion 257-344. http://dx.doi.org/10.1006/smim.2000.0253.